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ORIGINAL RESEARCH
Objectives: Parkinson’s disease (PD) is associated with motor fluctuations that have been
shown to improve when stable plasma levodopa levels are achieved with continuous levodopa
infusions. Many patients also develop mood fluctuations. In this pilot study, we gathered
preliminary information about the relationship between changing mood states and plasma
levodopa levels.
Methods: Six patients with idiopathic PD and histories of motor and mood fluctuations
participated in a double-blind levodopa infusion study. Subjects received active oral carbidopa/
levodopa and a placebo levodopa infusion on one day and placebo oral carbidopa/levodopa
and an active levodopa infusion on the other day, in a randomly determined order. Evaluations
included serial plasma levodopa levels and assessments of mood and motor states.
Results: Only 4 of the 6 subjects demonstrated mood fluctuations on at least one of the
treatment days. All subjects achieved more stable plasma levodopa levels on the active infusion
day. Two subjects experienced fewer mood fluctuations on the active infusion day and two
experienced fewer on the oral day.
Conclusions: The results of this pilot study suggest that the relationship between mood state
and plasma levodopa level may vary among PD patients.
Keywords: Parkinson’s disease, mood, fluctuations, levodopa
Introduction
Fluctuations in mood have been reported to occur in up to two-thirds of advanced
Parkinson’s disease (PD) patients who experience motor fluctuations (Nissenbaum
et al 1987). These can be frequent (occurring many times a day), dramatic (patients
can shift from very depressed and suicidal to euphoric), and can be more distressing
to the patients than the motor fluctuations. Research involving the phenomenology
and underlying mechanisms of mood fluctuations in PD has been limited.
Many researchers who have described mood fluctuations indicate that they are
linked to the motor fluctuations. The most commonly described pattern is that patients
experience lower mood when “off” (immobile, parkinsonian) and elevated mood
when “on” (mobile) (Hardie et al 1984; Cantello et al 1986; Friedenberg and
Cummings 1989; Lees 1989). However, another study found that some patients feel
well when “on” but experience worsening of mood when either “off” or “on with
dyskinesias” (Menza et al 1990). These observations led to the hypotheses that mood
fluctuations are either: (1) a psychological reaction to motor dysfunction, or (2)
manifestations of changing brain dopamine levels.
Investigators who studied intravenous infusions of levodopa in eight PD patients
with motor fluctuations demonstrated that both mood states were dose-responsive
but that the timing of mood and motor alterations were somewhat discordant, providing
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support for the notion that mood changes are not simply a
reaction to motor function (Maricle et al 1995).
In an attempt to better understand mood fluctuations,
we asked 17 patients with PD and motor fluctuations to
complete hourly diaries for seven days, documenting their
mood, anxiety, and motor states using visual analog scales
(Richard et al 2001). We were surprised by our finding that
although mood fluctuations appeared to be common in this
sample, there was no consistent relationship between mood
and motor states. We concluded that: (1) mood fluctuations
are not merely a psychological reaction to motor state; and
(2) mood and motor fluctuations may be, at least in some
patients, the result of different underlying patho-
physiological mechanisms.
Motor fluctuations in PD have been studied more
extensively than mood fluctuations and they are thought to
be due to a combination of disease progression and
antiparkinsonian medication therapy (Fahn 1999). As
dopaminergic neurons degenerate, the neuronal uptake of
levodopa and storage and release of dopamine become
poorly regulated. There is, in fact, a loss of “motoric
homeostasis” and the majority of patients start to experience
motor fluctuations within 5 years of beginning levodopa
(Poewe 1993). Studies have shown that motor fluctuations
can be improved, and even eliminated, if plasma levodopa
(and therefore brain dopamine) levels can be maintained
constant. This has been effectively done with intraduodenal
(Kurlan 1990) and intravenous levodopa infusions (Juncos
et al 1990).
The aim of the present study was to gather information
about the relationship between mood fluctuations and
plasma levodopa levels. We hypothesized that mood
fluctuations would be the immediate and direct result of
varying brain dopamine levels and that continuous
intravenous levodopa infusion, which leads to steady plasma
drug levels and is known to ameliorate motor fluctuations,
would reduce mood fluctuations.
Materials and methods
Patient selection
Six subjects with idiopathic PD and clinical histories of
mood and motor fluctuations provided informed consent
for study participation and were admitted to the General
Clinical Research Center (GCRC) at the University of
Rochester. The University of Rochester Institutional Review
Board approved the study. Subjects were recruited from the
University of Rochester Movement Disorders Center and
all had been diagnosed with idiopathic PD by neurologists
with subspecialty training in movement disorders. The
diagnosis was based on careful history and neurologic exam
(as well as diagnostic studies as indicated), and all patients
demonstrated at least three of the four cardinal signs of PD:
rigidity, bradykinesia, rest tremor, and postural instability.
Patients all demonstrated a clear-cut response to levodopa
therapy, and had no evidence of dementia.
Clinical histories of mood fluctuations were based on
the results of questionnaires completed by the subjects. A
subject was considered to have mood fluctuations based on
an affirmative response to a question regarding their
presence. The presence of motor fluctuations was based on
response to a similar question and then confirmed by treating
physicians who further characterized motor fluctuations as
any or all of the following: (1) dyksinesias, (2) wearing off,
and (3) “on–off” fluctuations. Subjects were also asked if
they had ever been diagnosed with and/or treated for
depression and/or anxiety. In preparation for the infusion
study, subjects who had clinical histories of motor and mood
fluctuations and who consented to participate in the study
were asked to complete diaries in which they report mood
and motor states on an hourly basis for seven days using
visual analog scales.
Levodopa administration
Subjects arrived at the GCRC in the afternoon of day one
and underwent physical and neurological exams. A
structured clinical interview, the “Structured Clinical
Interview for DSM-IV” (SCID) (Spitzer et al 1992) was
performed by a trained examiner to yield both lifetime and
current DSM-IV psychiatric diagnoses (APA 2000).
Subjects received instruction and practiced completing the
visual analog scales (see below). There were no dietary
restrictions on this day and subjects maintained their usual
antiparkinsonian medication regimen until the start of the
infusion the next morning.
The subjects then had two treatment days. On one of the
days, subjects received active oral carbidopa/levodopa (and
active entacapone in the case of subjects who had been
taking it with their carbidopa/levodopa) according to their
usual dosage regimen and a placebo levodopa infusion
(8 am–4 pm) with placebo oral carbidopa (and placebo
entacapone if indicated). On the other day, they received
placebo oral carbidopa/levodopa and an active levodopa
infusion (8 am–4 pm) with active oral carbidopa (and active
entacapone if indicated). The treatment assignments wereNeuropsychiatric Disease and Treatment 2005:1(3) 263
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random and were blinded from all study personnel except
the pharmacist. The blind was maintained by using a placebo
infusion of normal saline in a covered container and by
encasing the subjects’ own carbidopa/levodopa (or placebo)
and entacapone in opaque capsules. Active or placebo
carbidopa was also provided in opaque capsules.
On each of the two treatment days, subjects received a
low protein (5 g) breakfast and lunch. Subjects had an
intravenous line placed in one arm and a heparin lock (to
draw blood samples) placed in the other by 8 am. These
lines remained in place until the infusion was stopped at the
end of the second treatment day.
Levodopa (or normal saline) was infused intravenously,
initially at a rate of 1 mg/kg/h. After the first and second
hours of infusion, an independent (not the clinical rater)
clinician adjusted the infusion rate to optimize the subjects’
motor status. Further adjustments beyond the second hour
were not permitted (in an attempt to maintain stable plasma
levels). Carbidopa (25 mg) or placebo carbidopa was
administered at 7 am, 9 am, 11 am, 1 pm, and 3 pm to prevent
nausea.
Subjects had three milliliters of blood drawn from the
heparin lock every 30 minutes to assess plasma levodopa
levels during both treatment days. Blood draws began just
prior to the start of the infusion and continued until it was
stopped. Keith Hyland, PhD, performed all plasma assays
using high performance liquid chromatography analysis
(Baylor Medical College, Houston, TX, USA).
Mood and motor assessments
Visual analog scales (VAS) were completed by the subjects
and used to quantify mood state at 30-minute intervals
during the infusions (8 am–4 pm) (McCormack et al 1988).
Each rating form for mood contained a horizontal 10-cm
line with the descriptive anchors “extremely sad” and
“extremely happy” at the ends and a 5-cm midpoint labeled
“normal” to help guide subjects. Subjects were instructed
to make a vertical line through the point on the scale that
best represented their mood states for that half-hour. A ruler
was used to measure the distance in centimeters from the
left-sided anchor to the subject’s mark in order to obtain a
VAS score. VAS assessing degree of mood changes has been
proven to be a valid and reliable method in psychiatric
studies and was used by Maricle et al (1995) and Menza et
al (1990) in their studies of mood states in PD.
Given the opportunity for direct and objective motor
assessment, a single examiner assessed motor function on
both treatment days at 60-minute intervals during the
infusions (8 am–4 pm) using the motor subset (Part III) of
the Unified Parkinson’s Disease Rating Scale (UPDRS)
(Fahn et al 1987). This measure takes about 10 minutes to
administer and is appropriate for frequent assessments.
Statistical analysis
Given the small sample size, the analyses are mainly
descriptive. However, the mean and variance were calculated
for levodopa levels for each treatment day. Wilcoxon signed-
rank tests were used to compare the oral and levodopa
infusion days in these regards.
Results
There were 5 women and one man with an average age of
65.2 years (range 56–76) and mean Hoehn and Yahr score
of 2.7 (range 2–3). Only 4 of the 6 subjects completed the
diaries (subjects 1, 2, 4, and 5). Case histories are briefly
summarized below and in Table 1 (which also includes
information about concomitant medications).
Subject 1 was a 57-year-old woman with a 16-year
history of PD (Hoehn and Yahr 1967, stage 3) who suffered
from difficult to manage “on–off” fluctuations. She reported
a diagnosis of and treatment for depression, confirmed on
SCID interview. Her diary revealed motor and mood
fluctuations that occurred several times each day and were
dramatic (VAS motor scores ranging from 3 to 97 and mood
scores ranging from 6 to 93 on a scale of 0–100 mm, with
50 being “normal”).
Subject 2 was a 71-year-old woman with a 6-year history
of PD (Hoehn and Yahr 1967, stage 2). Her motor
fluctuations were characterized mainly by wearing off. She
did not experience significant dyskinesias. She denied any
psychiatric history, which was confirmed on SCID interview.
Her diary revealed mood and motor fluctuations in which
she reported low mood during periods of reduced mobility.
This was consistent over the 7-day period. She never
reported higher than “normal” mood or mobility.
Subject 3 was a 67-year-old woman with a 20-year
history of PD (Hoehn and Yahr 1967, stage 3) who suffered
from mild motor fluctuations characterized by wearing off
and dyskinesias. She reported a diagnosis of and treatment
for depression, which was confirmed on SCID interview.
She did not complete a diary. During the interview that was
conducted as part of the research study, she reported periods
of low mood alternating with periods of normal mood.Neuropsychiatric Disease and Treatment 2005:1(3) 264
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Subject 4 was a 64-year-old man with a 12-year history
of PD (Hoehn and Yahr 1967, stage 3) who suffered from
mild motor fluctuations characterized by wearing off and
dyskinesias. He denied a psychiatric history but was noted
to have depressive and anxiety diagnoses on SCID interview.
He completed a diary which revealed motor and mood
fluctuations that were mild and varied in severity from day
to day.
Subject 5 was a 76-year-old woman with a 12-year
history of PD (Hoehn and Yahr 1967, stage 2.5) who suffered
from mild motor fluctuations characterized by wearing off
and dyskinesias. She denied a psychiatric history, which
was confirmed on SCID interview. She completed a diary
which revealed mild motor fluctuations characterized
primarily by periods of increased mobility (dyskinesias) and
mild mood fluctuations which varied from day to day.
Subject 6 was a 56-year-old woman with a 5-year history
of PD (Hoehn and Yahr 1967, stage 3). She suffered from
motor fluctuations characterized by wearing off and
dyskinesias. She reported a history of anxiety. SCID
interview revealed threshold depressive, anxiety, and
psychotic symptoms. She did not complete a diary. During
the interview that was conducted as part of the research
study, she and her husband reported that she experienced
significant mood swings and also had episodes of pain,
primarily in her hands. They thought that these “non-motor”
episodes may represent wearing off of levodopa effects.
Three participants were given active infusions on day
one of treatment, and three were given them on day two.
All patients tolerated the infusions well and no adverse
events were reported. As a group, there was significantly
more variance in levodopa levels during oral levodopa
compared with infusion levodopa (p = 0.03). The average
levodopa level was not, however, statistically different
between the two modes of administration (p = 1).
Although all subjects had some variation in mood VAS
scores throughout the course of each treatment day, only
four of the subjects demonstrated prominent mood
fluctuations on at least one of the study days. Subjects 1
and 2 (Figure 1) demonstrated both mood and motor
fluctuations on the oral levodopa day that were much less
prominent on the active infusion day (when plasma levodopa
levels were relatively stable). Subjects 4 and 6 (who had
very minor motor fluctuations), demonstrated greater mood
Table 1 Clinical characteristics of study participants
Patient Sex Age H & Y SCID diagnoses Baseline UPDRS Concomitant medications
1 F 57 3 Mood disorder (depression) due to 29.5 C/L 25/100 7.5 tabs over 8 doses
general medical condition (GMC) “On” with dyskinesias C/L CR 25/100 qd
amantadine 100 mg BID
pramipexole 0.75 mg TID
midodrine 5 mg TID
quetiapine 12.5 mg
sertraline 100 mg
2 F 71 2 No diagnosis 29.5 C/L 25/100 × 5
Turned “on” during exam C/L CR 50/200 qd
entacapone 200 mg × 5
selegiline 5 mg
3 F 67 3 Major depressive disorder (MDD) 56 C/L 25/100 × 6
“On” pramipexole 1.5 mg TID
amantadine 100 mg BID
citalopram 40 mg
4 M 64 3 (1) MDD, threshold, mild, recurrent 53.5 C/L 25/100 × 6
(2) Generalized Anxiety Disorder (GAD) “On” C/L CR 50/200 × 6
ropinerole 2.0mg × 6
5 F 76 2.5 No diagnosis 33.5 C/L 25/100 QID
“On” with mild C/L CR 50/200 QID
dyskinesias pramipexole 1.5 mg TID
6 F 56 3 (1) Mood disorder due to GMC, threshold  49.5 C/L 25/100 × 6
(2) Psychotic symptoms, threshold “On” with dyskinesias pramipexole 1 mgTID
(3) Panic disorder, threshold lorazepam 1 mg (1/2 qhs)
(4) GAD, threshold
Abbreviations: C/L, carbidopa/levodopa; BID, twice a day; H & Y, Hoehn and Yahr; qd, every day; qhs, once at bedtime; QID, four times a day; SCID, Structured Clinical
Interview for DSM-IV; TID, three times a day; UPDRS, Unified Parkinson’s Disease Rating Scale.Neuropsychiatric Disease and Treatment 2005:1(3) 265
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Figure 1 Oral and infusion levodopa days of subjects who had fewer mood fluctuations on the active levodopa infusion day. These subjects demonstrate the “classic”
relationship between mood and motor states (mood is low during periods of decreased mobility). Abbreviations: UPDRS, Unified Parkinson’s Disease Rating Scale;
VAS, visual analog scale.
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Figure 2 Oral and levodopa days of subjects who had more mood fluctuations on the active levodopa infusion day. These subjects had very minor variations in
motor states.
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fluctuations on the active infusion day (when plasma
levodopa levels were relatively stable), as depicted in
Figure 2. Subjects 1, 4, and 6 demonstrated “bipolar” mood
fluctuations (with VAS mood scores both above and below
“normal”), whereas Subject 2’s mood fluctuated only
between “normal” and low.
Subject 3 had minimal variation in mood on both days
and mild motor fluctuations on the oral day that were not
present on the infusion day. Subject 5 had minimal variation
in mood and motor function on the oral day. On the infusion
day, the levodopa infusion rate was too low. The start of the
infusion was associated with a sharp decline in levodopa
level, followed by a decline in mood and motor function.
The levodopa level rose slightly but remained low
throughout the day, motor function improved slightly (but
remained worse than on oral levodopa) and mood gradually
improved and remained “normal”.
Discussion
Our pilot study demonstrated that the response of mood to
continuous intravenous infusions of levodopa varied among
subjects. The study had several strengths. The randomized,
double blind, placebo-controlled design served to eliminate
bias that is critical in assessing subjective outcomes such as
mood. A standard rating scale completed by a trained rater
served to provide objective measures of motor state. Ratings
of mood and motor function were performed prospectively
at frequent intervals. A standard psychiatric interview was
utilized to accurately assess current and past psychiatric
disorders. Finally, plasma levodopa assays confirmed that,
in general, levodopa infusions resulted in steadier plasma
levels.
The study also had limitations, including small sample
size and observations on only two days, which might
influence the interpretation of our results. There are inherent
but unavoidable limitations associated with studying
emotional states in “artificial” environments. Only 4 of the
6 subjects demonstrated prominent (“classic”) mood
fluctuations during the period of study.
Two subjects experienced a clear reduction in mood
fluctuations during the levodopa infusion. These subjects
both had motor fluctuations and demonstrated the most
commonly described pattern of mood/motor fluctuations
whereby patients are depressed when “off” and euthymic
or euphoric when “on”. While we cannot rule out the
possibility that mood changes were reactive to motor
changes, prior research fails to support this mechanism
(Maricle et al 1995; Richard et al 2001). A more plausible
theory is that for some patients fluctuations in mood, like
fluctuations in motor state, directly reflect changes in plasma
levodopa (and presumably brain dopamine) levels. For these
patients, therapeutic strategies aimed at achieving steadier
levodopa levels, such as controlled-release levodopa,
narrowing levodopa dosing intervals, or adding a COMT
inhibitor, should be helpful in reducing fluctuations in mood.
Two other subjects (both of whom had very minor motor
fluctuations) had mood fluctuations that did not appear to
be related to alterations in plasma levodopa levels or motor
state. It is possible that for some patients mood is determined
by a different neurochemical mechanism. There is ample
evidence suggesting a significant role for serotonin and
norepinephrine in the occurrence of mood and anxiety
disturbances in primary psychiatric populations and in PD
(Mayeux et al 1984; Schiffer et al 1988; Paulus and Jellinger
1991; Green et al 1995; Kostic et al 1996; Richard et al
1996; Menza et al 1999; Murai et al 2001). Alternatively, in
some patients there may be a more indirect, delayed effect
of levodopa (perhaps via other neurotransmitter systems)
so that the temporal relationship between plasma levodopa
level and mood state is not easily discernable.
Even in patients whose minute-to-minute mood states
are not related to plasma levodopa, it is possible that
dopaminergic dysregulation somehow “sets the stage” for
a loss of affective homeostasis. Evidence for general
homeostatic dysfunction in PD includes a wide variety of
symptom fluctuations, including motor, mood, anxiety,
cognitive, sensory, and autonomic forms, at least some of
which develop virtually inevitably after several years of
illness and treatment with dopaminergic medications. In
support of a dopamine dysregulation role in homeostatic
mood dysfunction is the finding that dopaminergic agents
can induce “rapid cycling” in patients with previously typical
bipolar illness (Ko et al 1981).
Although the small sample size limits our ability to draw
definitive conclusions, there were no clear demographic or
clinical factors that distinguished the two subjects whose
fluctuations improved with infusion from the subject whose
did not. For example, although one might hypothesize that
an underlying psychiatric disorder or current treatment with
an antidepressant medication would have an impact on
response to the infusions, we found no evidence for this
(see Table 1). Furthermore, direction of mood swings also
failed to distinguish those who responded to the levodopa
infusion from the ones who did not. One of the two infusion-
responders had “bipolar” mood fluctuations (ranging from
very elevated to very low mood), whereas the otherNeuropsychiatric Disease and Treatment 2005:1(3) 268
Richard et al
fluctuated in a “unipolar” pattern (only between normal and
low mood).
Further research is needed to improve our understanding
of the phenomenology and neurobiologic mechanisms
underlying changes in mood states in patients with PD so
that we may provide more rational therapy for this frequent
and distressing aspect of the disorder. Studies involving more
subjects, with longer observation periods and ensuring
optimization of infusion rates may overcome some of the
limitations of our study. Functional imaging studies done
during different mood states may prove technically
challenging in patients with PD-related motor symptoms
but they have the potential to help our understanding of the
neurobiologic underpinning of mood states. It is also likely
that research involving deep brain stimulation-related mood
changes will enable us to better clarify the neural circuitry
responsible for regulating mood. Given the fact that not all
PD patients develop fluctuations in mood, examination of
those characteristics that render some patients susceptible
to (or protected from) such fluctuations may provide
additional insights.
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